News | August 23, 2011

UltraSPECT Dose NM/PET Reduction Systems Installed at Multiple Sites

August 23, 2011— UltraSPECT of Haifa, Israel, announced the sale of more than 10 of its wide beam reconstruction (WBR) software solutions to nuclear pharmaceutical supplier PCI for placement at customer medical facilities throughout Arizona. PCI is a member of United Pharmacy Partners Inc. (UPPI), a nuclear pharmacy network consortium that recently signed a multi-year distribution agreement for the leasing and/or non-exclusive sales of UltraSPECT’s cardiac and bone imaging applications in the United States.

WBR is an innovative technology addressing current concern about patient radiation exposure. It enhances the performance of gamma cameras and PET scanners to enable a 50 percent reduction in injected dose and/or imaging procedure time with no decrease in image quality and while enhancing image resolution.

WBR’s lower dose requirements offer the benefits of minimizing radiation exposure for both patients and technologists, while abbreviated acquisition times reduce the possibility of patient motion artifacts and enhance patient throughput and comfort. Higher image resolution provides greater lesion localization, raising diagnostic confidence and precision. For many WBR users, the result is enhanced equipment utilization, revenues, patient satisfaction and referrals.

UltraSPECT’s enhanced WBR can either cut 50 percent of standard radiopharmaceutical dose requirements or reduce imaging scan time to a quarter of what it was before, while maintaining full image quality. The most recent WBR application allows both reduction in dose and scan time. This technology can be utilized with most major manufacturers’ nuclear medicine (NM) and positron emission tomography (PET) systems, as well as all clinical software packages.

Tri-City Cardiology Consultants of Mesa, Ariz., recently acquired the technology through PCI. Commenting on its recent WBR installation, Michelle Smudde, office manager at the cardiology group, said, "WBR technology has been easily accepted by our physicians and technologists. The implementation of the software among our fellow practices went pretty quickly." 

Ridge Smidt, Pharm D., owner of PCI Nuclear Pharmacy, added, “The Tri-City WBR installation demonstrates the power of WBR in reducing patient radiation exposure without sacrificing image quality and diagnostic accuracy. If all our nuclear medicine customers were to adopt the technology and incorporate WBR into their general practice, everyone involved would benefit – patients, physicians, technologists, pharmacies and pharmacy staff.”

For more information: www.ultraspect.com, www.pcinuclear.com

 

Related Content

Novel PET Tracer Clearly Identifies and Tracks Bacterial Lung Infection

Representative PET/CT images of 18F-FDS and 18F-FDG in inflamed mice. Mice were inoculated with dead K. pneumoniae (10^8 CFU/mL). Imaging was performed for days 1, 2, 3 and 4 using 18F-FDG and 18F-FDS. CT images showed clear inflammation on day 2 and day 3 with corresponding high 18F-FDG uptake on PET. No significant uptake of 18F-FDS was detected for any of those 4 days. Credit: J Li et al., University of Louisville School of Medicine, Louisville, Ky.

News | PET-CT | January 22, 2018
January 22, 2018 — Researchers at the University of Louisville, Kentucky, have demonstrated that a new...
PET Tracer Gauges Effectiveness of Promising Alzheimer's Treatment

Longitudinal PET imaging with 18F-AV45. PET imaging shows the average 18F-AV45 uptake per animal group at 8 and 13 months of age. A significant interaction of genotype treatment was observed in the cortex (p = 0.0248), hippocampus (p = 0.0071) and thalamus (p = 0.0084), indicating reduced [18F]-AV45 uptake in BACE1 inhibited transgenic mice. Credit: MICA, University of Antwerp, Belgium.

News | Radiopharmaceuticals and Tracers | December 28, 2017
In the December featured basic science article in The Journal of Nuclear Medicine, Belgian researchers report on the...
Vital Unveils Newest Vitrea Advanced Visualization Release at RSNA 2017
Technology | Advanced Visualization | December 04, 2017
Vital Images unveiled the newest version of Vitrea Advanced Visualization software, the cornerstone of its imaging...
Michael J. Fox Foundation and Tau Consortium Developing PET Tracers for Neurodegenerative Disease
News | Radiopharmaceuticals and Tracers | October 27, 2017
The Michael J. Fox Foundation for Parkinson's Research (MJFF) and the Tau Consortium announced a funding partnership to...
Netherlands Cancer Institute Exploring Molecular Imaging Technology for Prostate Cancer Surgery
News | Molecular Imaging | October 26, 2017
The Netherlands Cancer Institute (NKI) announced it has received funding from the Dutch Cancer Society (KWF...
SNMMI Publishes New FDG PET/CT Appropriate Use Criteria
News | PET-CT | October 25, 2017
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published appropriate use criteria (AUC) for FDG PET/...
Biodex Unveils Atomlab 500 Dose Calibrator and Wipe Test Counter
Technology | Nuclear Imaging | October 19, 2017
Biodex Medical Systems announced the full release of the Atomlab Dose Calibrator and Wipe Test Counter to the market...
ASNC and ASE Team Up to Expand ImageGuide Registry
News | Cardiovascular Ultrasound | October 12, 2017
The American Society of Nuclear Cardiology (ASNC) and the American Society of Echocardiography (ASE) jointly announced...
MR Solutions Showcases Multimodality MRI Solutions on Two Continents
News | Magnetic Resonance Imaging (MRI) | October 11, 2017
October 11, 2017 — MR Solutions took their cryogen-free preclinical multimodality...
Majority of Recurrent Prostate Cancer Patients' Treatment Plan Changed Following Fluciclovine 18F PET/CT
News | Prostate Cancer | October 04, 2017
Blue Earth Diagnostics recently announced the results of a pre-planned interim analysis from an investigational...
Overlay Init